SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Poseida
Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage
biopharmaceutical company dedicated to utilizing its proprietary
gene engineering platform technologies to create next generation
cell and gene therapeutics with the capacity to cure, today
announced its addition as a member of the US small-cap Russell
2000® Index, effective September 18, 2020, as part of the index's
quarterly initial public offering (IPO) additions.
"We are pleased to be added to the US small-cap Russell 2000
Index, which will help increase investor exposure to our Company's
mission of providing cell and gene therapies for patients with high
unmet medical need," said Eric
Ostertag, M.D., Ph.D., Chief Executive Officer
of Poseida. "We look forward to the opportunity to expand
awareness around our pipeline of differentiated product candidates
for the treatment of a variety of oncology indications and orphan
genetic diseases."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets are benchmarked against
Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
For more information on the Russell 2000® Index and
the Russell indexes IPO additions, please visit the "Russell U.S.
Index IPO Additions" section on the FTSE Russell website.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company dedicated to
utilizing our proprietary gene engineering platform technologies to
create next generation cell and gene therapeutics with the capacity
to cure. We have discovered and are developing a broad portfolio of
product candidates in a variety of indications based on our core
proprietary platforms, including our non-viral
piggyBac® DNA Modification System, Cas-CLOVER™
site-specific gene editing system and nanoparticle- and AAV-based
gene delivery technologies. Our core platform technologies have
utility, either alone or in combination, across many cell and gene
therapeutic modalities and enable us to engineer our wholly-owned
portfolio of product candidates that are designed to overcome the
primary limitations of current generation cell and gene
therapeutics.
About FTSE Russell
FTSE Russell is a leading global
index provider creating and managing a wide range of indexes, data
and analytic solutions to meet client needs across asset classes,
style and strategies. Covering 98% of the investable market, FTSE
Russell indexes offer a true picture of global markets, combined
with the specialist knowledge gained from developing local
benchmarks around the world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$16 trillion is currently benchmarked
to FTSE Russell indexes. For over 30 years, leading asset owners,
asset managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create investment funds, ETFs, structured products and index-based
derivatives. FTSE Russell indexes also provide clients with tools
for asset allocation, investment strategy analysis and risk
management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit www.ftserussell.com
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements regarding the impact of Poseida's
addition to the US small-cap Russell 2000® Index,
the potential benefits of Poseida's technology platforms
and product candidates and Poseida's plans and strategy
with respect to developing its technologies and product candidates.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. These forward-looking
statements are based upon Poseida's current expectations
and involve assumptions that may never materialize or may prove to
be incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with development and regulatory
approval of novel product candidates in the biopharmaceutical
industry and the other risks described
in Poseida's filings with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Poseida undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/poseida-therapeutics-added-to-membership-of-us-small-cap-russell-2000-index-301133716.html
SOURCE Poseida Therapeutics, Inc.